Reference : Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know.
Scientific journals : Article
Human health sciences : Laboratory medicine & medical technology
Human health sciences : Urology & nephrology
http://hdl.handle.net/2268/218913
Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know.
English
DELANAYE, Pierre mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie >]
PAQUOT, Francois mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie >]
BOUQUEGNEAU, Antoine mailto [Centre Hospitalier Universitaire de Liège - CHU > > Service de néphrologie >]
Blocki, Frank [> >]
Krzesinski, Jean-Marie mailto [Université de Liège - ULiège > Département des sciences cliniques > Néphrologie >]
Evenepoel, Pieter [> >]
Pottel, Hans [> >]
Cavalier, Etienne mailto [Université de Liège - ULiège > Département de pharmacie > Chimie médicale >]
2018
Nephrology Dialysis Transplantation
33
8
1404-1410
Yes (verified by ORBi)
International
0931-0509
1460-2385
England
[en] PTH ; biomarkers ; chronic hemodialysis ; chronic kidney disease ; sclerostin
[en] Background: Sclerostin, a 22-kDa protein secreted by osteocytes, acts as a potent inhibitor of osteoblast activity. In chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular axis. However, large discrepancies between sclerostin assays have been described. Methods: We compared four different assays [Biomedica (BM), TecoMedical (TE), R&D (RD) and MesoScaleDiscovery (MSD)] in an analytical study and addressed the question whether bioassay choice affects the correlation between circulating sclerostin and clinical and biochemical determinants. Circulating sclerostin levels were determined in 39 prevalent dialysis patients and 82 non-dialysis patients referred for glomerular filtration rate measurement. Results: In the 82 non-dialysis patients, we observed large differences in median (interquartile range) sclerostin concentrations (in pg/mL): BM, 984 [interquartile range (IQR) 648]; TE, 629 (IQR 237); RD, 154 (IQR 84) and MSD, 36 (IQR 19). The concordance correlation coefficient between assays was poor (0.1-0.44). The same discrepancies were observed in dialysis patients. A significant negative rank correlation was found between glomerular filtration rate and sclerostin measured by BM and TE but not by MSD and RD. Associations between sclerostin and age, gender, weight or parathormone were also different according to the assay considered. Conclusions: Clinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker.
http://hdl.handle.net/2268/218913
10.1093/ndt/gfx282

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
gfx282.pdfPublisher postprint652.02 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.